{
    "id": 89,
    "premise": "none",
    "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC",
    "label": "entailment",
    "explanation": "US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC",
        "history explanation": [
            "0 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "1 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "2 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "3 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "4 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "5 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "6 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
            "7 iteration: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nThe treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib.",
            "8 iteration: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nThe treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib.",
            "9 iteration: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nThe treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib.",
            "10 iteration: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nThe treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.462839603424072, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Treatment :: entity \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (x, y) :: entity \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 entity \u21d2 bool\"\\n  TumourSpecificDefectsInDNARepair :: \"entity\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 (\u2200z. Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u27f6 Treatment y z)\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Olaparib x \u2227 Talazoparib x \u2227 PARPInhibitor x \u2227 Licensed x \u2227 Target x TumourSpecificDefectsInDNARepair\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient(y) \u2227 BRCA_mutated(y) \u2227 HER_2_negative(y) \u2227 (Advanced(y) \u2228 Metastatic(y))\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"\u2200x. Olaparib(x) \u2227 Talazoparib(x) \u2227 PARPInhibitor(x) \u2227 Licensed(x) \u2227 Treatment(x, y)\"\\nproof -\\n  (* From the premise, we have information about the patient being BRCA-mutated, HER-2-negative, and either advanced or metastatic. *)\\n  from asm have \"Patient(y) \u2227 BRCA_mutated(y) \u2227 HER_2_negative(y) \u2227 (Advanced(y) \u2228 Metastatic(y))\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair) *)\\n  (* We can infer that PARP inhibitors target tumor-specific defects in DNA repair from the premise. *)\\n  then have \"PARPInhibitor(x) \u2227 Target(x, TumourSpecificDefectsInDNARepair)\" for x <ATP>\\n  (* From explanatory sentence 2, we know that Olaparib and Talazoparib are licensed PARP inhibitors. *)\\n  then have \"Olaparib(x) \u2227 Talazoparib(x) \u2227 PARPInhibitor(x) \u2227 Licensed(x)\" for x <ATP>\\n  (* Finally, we can conclude that Olaparib and Talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.679445028305054, 'proof tactics': ['Inner syntax error\\\\<^here>\\nFailed to parse prop', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  BC :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  SpecificDefects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u2227 BC z\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. (Olaparib x \u2227 Talazoparib x) \u27f6 (PARPInhibitor x \u2227 Licensed x \u2227 (\u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y))\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n shows \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are both present. *)\\n  from asm have \"Olaparib x \u2227 Talazoparib x\" <ATP>\\n  (* We have the logical relation Implies(B, C), which states that if Olaparib and Talazoparib are licensed PARP inhibitors, then PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  (* Using this relation and Explanation 2, we can infer that Olaparib and Talazoparib are PARP inhibitors that target tumor-specific defects in DNA repair. *)\\n  from asm and explanation_2 have \"PARPInhibitor x \u2227 Licensed x \u2227 (\u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y)\" <ATP>\\n  (* Since the patients with BRCA-mutated, HER-2-negative advanced or metastatic BC are treated with PARP inhibitors targeting tumor-specific defects in DNA repair, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.45702052116394, 'proof tactics': ['Inner syntax error\\\\<^here>\\nFailed to parse prop', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  BC :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  SpecificDefects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u2227 BC z\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. (Olaparib x \u2227 Talazoparib x) \u27f6 (PARPInhibitor x \u2227 Licensed x \u2227 (\u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y))\"\\n\\ntheorem hypothesis:\\n assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n shows \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are both present. *)\\n  from asm have \"Olaparib x \u2227 Talazoparib x\" <ATP>\\n  (* We have the logical relation Implies(B, C), which states that if Olaparib and Talazoparib are licensed PARP inhibitors, then PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  (* Using this relation and Explanation 2, we can infer that Olaparib and Talazoparib being licensed PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  from asm and explanation_2 have \"PARPInhibitor x \u2227 Licensed x \u2227 (\u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y)\" <ATP>\\n  (* Since we are interested in patients with specific characteristics, we can further infer the desired conclusion. *)\\n  then have \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.596451997756958, 'proof tactics': ['Inner syntax error\\\\<^here>\\nFailed to parse prop', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  BC :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  SpecificDefects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u2227 BC z\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. (Olaparib x \u2227 Talazoparib x) \u27f6 (PARPInhibitor x \u2227 Licensed x \u2227 (\u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y))\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are both present. *)\\n  from asm have \"Olaparib x \u2227 Talazoparib x\" <ATP>\\n  (* Using the logical relation Implies(B, C), we can infer that Olaparib and Talazoparib being licensed PARP inhibitors implies that PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  (* This relation is derived from explanatory sentence 2. *)\\n  then have \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Tumour y \u2227 SpecificDefects y \u2227 DNARepair y\" <ATP>\\n  (* Since we are interested in patients with specific characteristics, we can further specify the properties of y. *)\\n  then have \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.144746541976929, 'proof tactics': ['Inner syntax error: unexpected end of input\\\\<^here>\\nFailed to parse prop', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFoodDrugAdministration :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  AdvancedBC :: \"entity \u21d2 bool\"\\n  MetastaticBC :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  LicensedPARPInhibitor :: \"entity \u21d2 bool\"\\n  TargetDefects :: \"entity \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  TumourSpecific :: \"entity \u21d2 entity\"\\n  DNARepair :: \"entity \u21d2 entity\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. USFoodDrugAdministration x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 (\u2200z. Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (AdvancedBC z \u2228 MetastaticBC z) \u27f6 Treatment y z)\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Olaparib x \u2227 Talazoparib x \u2227 LicensedPARPInhibitor x \u2227 TargetDefects x (TumourSpecific x) (DNARepair x)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient(y) \u2227 BRCA_mutated(y) \u2227 HER_2_negative(y) \u2227 (AdvancedBC(y) \u2228 MetastaticBC(y))\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"\u2203x. Olaparib(x) \u2227 Talazoparib(x) \u2227 LicensedPARPInhibitor(x) \u2227 (\u2200y. Patient(y) \u2227 BRCA_mutated(y) \u2227 HER_2_negative(y) \u2227 (AdvancedBC(y) \u2228 MetastaticBC(y)) \u27f6 Treatment(x, y)\"\\nproof -\\n  (* From the premise, we have information about the patient being BRCA-mutated, HER-2-negative, and having advanced or metastatic BC. *)\\n  from asm have \"Patient(y) \u2227 BRCA_mutated(y) \u2227 HER_2_negative(y) \u2227 (AdvancedBC(y) \u2228 MetastaticBC(y))\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair) *)\\n  (* Both A and C are from explanatory sentences 1 and 2. *)\\n  (* We can infer that PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  then have \"PARP inhibitors target tumor-specific defects in DNA repair\" <ATP>\\n  (* There is a derived implication Implies(Not(C), Not(A)), Implies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC)) *)\\n  (* Since we have C, we can conclude A. *)\\n  then have \"US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.78717851638794, 'proof tactics': ['Inner syntax error\\\\<^here>\\nFailed to parse prop', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  BC :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  SpecificDefects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u2227 BC z\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Olaparib x \u2227 Talazoparib x \u27f6 PARPInhibitor x \u2227 Licensed x \u2227 Tumour y \u2227 SpecificDefects y \u2227 DNARepair y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are both present. *)\\n  from asm have \"Olaparib x \u2227 Talazoparib x\" <ATP>\\n  (* We have the logical relation Implies(B, C), which states that if Olaparib and Talazoparib are licensed PARP inhibitors, then PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  (* Since Olaparib and Talazoparib are licensed PARP inhibitors, we can infer that PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  from explanation_2 and asm have \"PARPInhibitor x \u2227 Licensed x \u2227 Tumour y \u2227 SpecificDefects y \u2227 DNARepair y\" <ATP>\\n  (* We also have the logical relation Implies(A, C), which states that if the US Food and Drug Administration approved Olaparib and Talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, then PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  (* Since the US Food and Drug Administration approved Olaparib and Talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, we can conclude that PARP inhibitors target tumor-specific defects in DNA repair. *)\\n  from explanation_1 have \"PARPInhibitor x \u2227 Licensed x \u2227 \u2203y. Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Combining the above inferences, we can conclude that Olaparib and Talazoparib are licensed PARP inhibitors for the treatment of the patient. *)\\nthen show ?thesis sledgehammer', 'solving time': 135.14156126976013, 'proof tactics': [], 'code': 'theory clinical_89_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Approved :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA_mutated :: \"entity \u21d2 bool\"\\n  HER_2_negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 entity \u21d2 bool\"\\n  TumourSpecificDefectsInDNARepair :: \"entity\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. USFDA x \u2227 Approved y \u2227 Olaparib y \u2227 Talazoparib y \u2227 (\u2200z. Patient z \u2227 BRCA_mutated z \u2227 HER_2_negative z \u2227 (Advanced z \u2228 Metastatic z) \u27f6 Treatment y z)\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair *)\\naxiomatization where\\n  explanation_2: \"\u2200x. Olaparib x \u2227 Talazoparib x \u2227 PARPInhibitor x \u2227 Target x TumourSpecificDefectsInDNARepair\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y)\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"\u2200x. Olaparib x \u2227 Talazoparib x \u2227 PARPInhibitor x \u2227 Treatment x y\"\\nproof -\\n  (* From the premise, we know the patient has specific characteristics related to the treatment. *)\\n  from asm have \"Patient y \u2227 BRCA_mutated y \u2227 HER_2_negative y \u2227 (Advanced y \u2228 Metastatic y)\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair) *)\\n  (* We can infer that PARP inhibitors target tumor-specific defects in DNA repair from the premise. *)\\n  then have \"PARPInhibitor x \u2227 Target x TumourSpecificDefectsInDNARepair\" for x <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair) *)\\n  (* We can infer that Olaparib and Talazoparib are licensed PARP inhibitors from the previous inference. *)\\n  then have \"Olaparib x \u2227 Talazoparib x\" for x <ATP>\\n  (* Combining the above inferences, we can conclude that Olaparib and Talazoparib are licensed PARP inhibitors for the treatment of the patient. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nB: Olaparib and talazoparib are licensed PARP inhibitors\\nC: PARP inhibitors target tumor-specific defects in DNA repair\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\nImplies(B, C)\\nImplies(Olaparib and talazoparib are licensed PARP inhibitors, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, PARP inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP inhibitors target tumor-specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_89_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  AdultSponges :: \"entity \u21d2 bool\"\\n  Eggs :: \"entity \u21d2 bool\"\\n  Sperm :: \"entity \u21d2 bool\"\\n  Produce :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Gametes :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  BRCAmutated :: \"entity \u21d2 bool\"\\n  HER2negative :: \"entity \u21d2 bool\"\\n  Advanced :: \"entity \u21d2 bool\"\\n  Metastatic :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Adult sponges produce eggs and sperm. *)\\naxiomatization where\\n  explanation_1: \"\u2200x. AdultSponges x \u27f6 (\u2203e y z. Eggs y \u2227 Sperm z \u2227 Produce e \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z)\"\\n\\n(* Explanation 2: Sperm and eggs are cells known as gametes. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Sperm x \u2227 Eggs y \u27f6 Gametes x \u2227 Gametes y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"\"\\n  shows \"(Olaparib x \u2228 Talazoparib x) \u27f6 (PARPInhibitor x \u2227 (\u2200y. Patient y \u2227 BRCAmutated y \u2227 HER2negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BreastCancer y))\"\\nproof -\\n  (* From the explanation 1, we know that AdultSponges produce eggs and sperm. *)\\n  have \"\u2203e y z. Eggs y \u2227 Sperm z \u2227 Produce e \u2227 Agent e AdultSponges \u2227 Patient e y \u2227 Patient e z\" by (rule explanation_1)\\n  (* From the explanation 2, we know that Sperm and eggs are gametes. *)\\n  then have \"Gametes z \u2227 Gametes y\" for z y by (rule explanation_2)\\n  (* Since the treatment includes Olaparib and Talazoparib, which are PARP inhibitors, we can infer PARPInhibitor x. *)\\n  assume \"(Olaparib x \u2228 Talazoparib x)\"\\n  then have \"PARPInhibitor x\" by auto\\n  (* For the patient y with specific characteristics, we have BRCA-mutated, HER-2-negative, advanced or metastatic BC, and BreastCancer. *)\\n  have \"Patient y \u2227 BRCAmutated y \u2227 HER2negative y \u2227 (Advanced y \u2228 Metastatic y) \u2227 BreastCancer y\" if \"Patient y\" for y <ATP>\\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: x is a PARP inhibitor\\nB: x targets tumor-specific defects in DNA repair\\nC: x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nD: y is a patient with specific characteristics\\nE: The treatment administered includes the PARP inhibitors Olaparib and Talazoparib\\n\\nLogical Relations:\\nImplies(And(A, B), C)\\nImplies(A & B, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nImplies(C, D)\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, y is a patient with specific characteristics)\\n--------\\nEquivalent(D, E)\\nEquivalent(y is a patient with specific characteristics, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(E))\\nImplies(Not(y is a patient with specific characteristics), Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib), Not(y is a patient with specific characteristics))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib), Not(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\nImplies(C, E)\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\nImplies(E, D)\\nImplies(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib, y is a patient with specific characteristics)\\n--------\\nImplies(D, E)\\nImplies(y is a patient with specific characteristics, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_89_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Targets :: \"entity \u21d2 entity \u21d2 bool\"\\n  TumorSpecificDefectsInDNARepair :: \"entity \u21d2 bool\"\\n  TreatmentFor :: \"entity \u21d2 bool \u21d2 bool \u21d2 bool \u21d2 bool\"\\n  BRCA :: \"entity \u21d2 bool\"\\n  HER :: \"entity \u21d2 bool\"\\n  AdvancedOrMetastaticBC :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  SpecificCharacteristics :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative, AdvancedOrMetastaticBC *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. (PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)) \u27f6 TreatmentFor x (BRCA y) (HER y) (AdvancedOrMetastaticBC y)\"\\n\\n(* Explanation 2: The treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib *)\\naxiomatization where\\n  explanation_2: \"\u2203y. Patient y \u2227 SpecificCharacteristics y \u2227 (TreatmentFor Olaparib (BRCA y) (HER y) (AdvancedOrMetastaticBC y)) \u2227 (TreatmentFor Talazoparib (BRCA y) (HER y) (AdvancedOrMetastaticBC y))\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n shows \"PARPInhibitor x \u2227 TreatmentFor x (BRCA x) (HER x) (AdvancedOrMetastaticBC x)\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are PARP inhibitors. *)\\n  from asm have \"PARPInhibitor x\" <ATP>\\n  (* We also know that the treatment administered includes Olaparib and Talazoparib for patients with specific characteristics. *)\\n  (* There is a logical relation Implies(E, C), Implies(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC) *)\\n  (* Since Olaparib and Talazoparib are used for the treatment, we can infer that they are used for patients with specific characteristics. *)\\n  then have \"TreatmentFor x (BRCA x) (HER x) (AdvancedOrMetastaticBC x)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: x is a PARP inhibitor\\nB: x targets tumor-specific defects in DNA repair\\nC: x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nD: y is a patient with specific characteristics\\nE: The treatment administered includes the PARP inhibitors Olaparib and Talazoparib\\n\\nLogical Relations:\\nImplies(And(A, B), C)\\nImplies(A & B, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nImplies(D, C)\\nImplies(y is a patient with specific characteristics, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nEquivalent(C, E)\\nEquivalent(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\n\\nDerived Implications:\\nImplies(E, C)\\nImplies(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib), Not(y is a patient with specific characteristics))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib), Not(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC), Not(The treatment administered includes the PARP inhibitors Olaparib and Talazoparib))\\n--------\\nImplies(C, E)\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\nImplies(D, E)\\nImplies(y is a patient with specific characteristics, The treatment administered includes the PARP inhibitors Olaparib and Talazoparib)\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.117886543273926, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  TreatmentFor x :: entity \\\\<Rightarrow> bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool \\\\<Rightarrow> bool\\nOperand:   BRCA :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_89_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Targets :: \"entity \u21d2 bool \u21d2 bool\"\\n  TumorSpecificDefectsInDNARepair :: \"entity \u21d2 bool\"\\n  TreatmentFor :: \"entity \u21d2 entity \u21d2 bool \u21d2 bool \u21d2 bool \u21d2 bool\"\\n  BRCA :: \"entity \u21d2 bool\"\\n  HER :: \"entity \u21d2 bool\"\\n  AdvancedOrMetastaticBC :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity\"\\n  Talazoparib :: \"entity\"\\n\\n(* Explanation 1: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative, AdvancedOrMetastaticBC *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. (PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)) \u27f6 TreatmentFor x y (BRCA y) (HER y) (AdvancedOrMetastaticBC y)\"\\n\\n(* Explanation 2: The treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib *)\\naxiomatization where\\n  explanation_2: \"\u2200y. TreatmentFor Olaparib y (BRCA y) (HER y) (AdvancedOrMetastaticBC y) \u2227 TreatmentFor Talazoparib y (BRCA y) (HER y) (AdvancedOrMetastaticBC y)\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n shows \"PARPInhibitor x \u2227 TreatmentFor x BRCA HER AdvancedOrMetastaticBC\"\\nproof -\\n  (* From the premise, we know that x is a PARP inhibitor and x targets tumor-specific defects in DNA repair. *)\\n  from asm have \"PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)\" <ATP>\\n  (* Using Explanation 1, we can infer that x is used for the treatment of the patient y with specific characteristics. *)\\n  from explanation_1 and \u2039PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)\u203a have \"TreatmentFor x BRCA HER AdvancedOrMetastaticBC\" <ATP>\\n  (* We also know from Explanation 2 that the treatment administered includes the PARP inhibitors Olaparib and Talazoparib. *)\\n  from explanation_2 have \"TreatmentFor Olaparib BRCA HER AdvancedOrMetastaticBC \u2227 TreatmentFor Talazoparib BRCA HER AdvancedOrMetastaticBC\" <ATP>\\n  (* Combining the above information, we can conclude that x is a PARP inhibitor and is used for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: x is a PARP inhibitor\\nB: x targets tumor-specific defects in DNA repair\\nC: x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nD: y is a patient with specific characteristics\\nE: The treatment administered includes the PARP inhibitors Olaparib\\nF: The treatment administered includes the PARP inhibitors Talazoparib\\n\\nLogical Relations:\\nImplies(And(A, B), C)\\nImplies(A & B, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nImplies(C, And(D, Or(E, F)))\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, D & (E | F))\\n--------\\n\\nDerived Implications:\\nImplies(C, D)\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, y is a patient with specific characteristics)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(y is a patient with specific characteristics), Not(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_89_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Targets :: \"entity \u21d2 entity \u21d2 bool\"\\n  TumorSpecificDefectsInDNARepair :: \"entity \u21d2 entity \u21d2 bool\"\\n  TreatmentFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  BRCA :: \"entity\"\\n  HER :: \"entity\"\\n  AdvancedOrMetastaticBC :: \"entity \u21d2 bool\"\\n  TreatmentAdministered :: \"entity \u21d2 bool\"\\n  IncludesTreatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  SpecificCharacteristics :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: For all entities x, if x is a PARP inhibitor and x targets tumor-specific defects in DNA repair, then x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative, AdvancedOrMetastaticBC. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. (PARPInhibitor x \u2227 Targets x (TumorSpecificDefectsInDNARepair x)) \u27f6 (TreatmentFor x y)\"\\n\\n(* Explanation 2: The treatment administered to the patient y with specific characteristics includes the PARP inhibitors Olaparib and Talazoparib. *)\\naxiomatization where\\n  explanation_2: \"\u2200y. (Patient y \u2227 SpecificCharacteristics y) \u27f6 (TreatmentAdministered y \u2227 IncludesTreatment y Olaparib \u2227 IncludesTreatment y Talazoparib)\"\\n\\n\\ntheorem hypothesis:\\n  assumes asm: \"Olaparib x \u2227 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC *)\\n  shows \"PARPInhibitor x \u2227 (\u2203y. TreatmentFor x y \u2227 BRCA y \u2227 HER y \u2227 AdvancedOrMetastaticBC y)\"\\nproof -\\n  (* From the premise, we know that Olaparib and Talazoparib are PARP inhibitors. *)\\n  from asm have \"PARPInhibitor x\" <ATP>\\n  (* We have an explanatory sentence stating that if an entity is a PARP inhibitor and targets tumor-specific defects in DNA repair, it is used for the treatment of a patient with specific characteristics. *)\\n  (* There is a logical relation Implies(And(A, B), C), Implies(A & B, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC) *)\\n  (* Since we have PARPInhibitor x, we can infer that x is used for the treatment of a patient with specific characteristics. *)\\n  then have \"\u2203y. TreatmentFor x y\" <ATP>\\n  (* We also know that the patient y with specific characteristics includes BRCA-mutated and HER-2-negative advanced or metastatic BC. *)\\n  then have \"\u2203y. TreatmentFor x y \u2227 BRCA y \u2227 HER y \u2227 AdvancedOrMetastaticBC y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: x is a PARP inhibitor\\nB: x targets tumor-specific defects in DNA repair\\nC: x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC\\nD: y is a patient with specific characteristics\\nE: The treatment administered includes the PARP inhibitors Olaparib\\nF: The treatment administered includes the PARP inhibitors Talazoparib\\n\\nLogical Relations:\\nImplies(And(A, B), C)\\nImplies(A & B, x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC)\\n--------\\nImplies(C, And(D, Or(E, F)))\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, D & (E | F))\\n--------\\n\\nDerived Implications:\\nImplies(C, D)\\nImplies(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC, y is a patient with specific characteristics)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(y is a patient with specific characteristics), Not(x is used for the treatment of the patient y with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\n'}"
        ]
    }
}